Watch for Nasdaq's conditional approval of the Initial Listing Application, which is a prerequisite for voting on Proposals 3-6 at the reconvened meeting on October 1, 2026. The expected resignation of both re-elected directors after all proposals pass signals a pending change of control — monitor for subsequent director appointments and any related party transactions.
Price Chart
Executive Summary
Adial Pharmaceuticals held its 2026 Annual Meeting on September 17, 2026, where stockholders approved the 2026 Equity Incentive Plan (3,078,147 share reserve plus annual increases), the 2026 Employee Stock Purchase Plan (307,815 shares plus annual increases), and Amendment No. 8 to the 2017 Plan (increasing shares from 200,000 to 225,666). The meeting was partially adjourned to October 1, 2026 for Proposals 3-6 pending Nasdaq conditional approval of an Initial Listing Application, while the two incumbent directors (Cary Claiborne and Robertson Gilliland) were re-elected but are expected to resign shortly after all proposals are approved, signaling a pending change of control.
Key Facts
- Stockholders approved the 2026 Equity Incentive Plan with a share reserve of 3,078,147 shares plus up to 196,670 returning shares and annual 5% evergreen increases through 2036
- Stockholders approved the 2026 Employee Stock Purchase Plan with 307,815 shares plus annual 1% evergreen increases through 2036
- Stockholders approved Amendment No. 8 to the 2017 Plan, increasing authorized shares from 200,000 to 225,666
- Stockholders approved an amendment to the certificate of incorporation to increase authorized common shares from 100,000,000 to 500,000,000
- Stockholders approved the 2025 Warrant Exercise Proposal for up to 552,940 shares upon exercise of Series F warrants
- Annual meeting partially adjourned to October 1, 2026 for Proposals 3-6 pending Nasdaq conditional approval of an Initial Listing Application
- Incumbent directors Cary J. Claiborne and Robertson H. Gilliland were re-elected but are expected to resign shortly after all proposals are approved
- 48.7% of outstanding shares (1,278,677 of 2,625,890) were present, constituting a quorum
Financial Impact
Significant equity dilution authorized: up to 3,078,147 shares under the 2026 Plan (plus evergreen increases) and 307,815 shares under the ESPP (plus evergreen increases), compared to 2,625,890 shares outstanding. The authorized share count was increased from 100M to 500M shares.
Risk Factors
- Massive potential dilution: the 2026 Plan reserve of ~3.1M shares exceeds the current outstanding share count of ~2.6M, and the authorized share count was quintupled to 500M
- Nasdaq conditional approval is still pending, creating uncertainty around the completion of Proposals 3-6 and the overall restructuring
- Expected director resignations after proposal approvals indicate a change of control is imminent, which could lead to significant corporate actions
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-101434 |
| Document: ea030593301ex10-3.htm | 0001213900-26-101434 |
| Document: ea0305933-8k_adial.htm | 0001213900-26-101434 |
| Document: ea030593301ex10-1.htm | 0001213900-26-101434 |
| Document: 0001213900-26-101434-index-headers.html | 0001213900-26-101434 |
| Document: 0001213900-26-101434-index.html | 0001213900-26-101434 |
| Document: 0001213900-26-101434.txt | 0001213900-26-101434 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | 10-Q/A | $4.11 | awaiting T+60 | — | $3.68 (+10.46%) |
Oct 20, 2026 6d ago | S-3/A | $4.11 | awaiting T+60 | — | $3.68 (+10.46%) |
Oct 16, 2026 10d ago | DEFA14A | $3.62 | awaiting T+60 | — | $3.68 (−1.66%) |
Oct 16, 2026 10d ago | 8-K | $3.62 | awaiting T+60 | — | $3.68 (−1.66%) |
Sep 30, 2026 26d ago | Press Release | $4.13 | awaiting T+60 | — | $3.68 (−10.90%) |
Sep 18, 2026 5w ago | DEFA14A | $4.40 | awaiting T+60 | — | $3.68 (−16.36%) |
Sep 18, 2026 5w ago | 8-K | $4.40 | awaiting T+60 | — | $3.68 (−16.36%) |
Sep 16, 2026 5w ago | DEFA14A | $5.21 | awaiting T+60 | — | $3.68 (−29.37%) |
Sep 16, 2026 5w ago | 8-K | $5.21 | awaiting T+60 | — | $3.68 (−29.37%) |
Aug 17, 2026 10w ago | 8-K | $4.99 | awaiting T+60 | — | $3.68 (−26.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers